Karuna Therapeutics Inc
Change company Symbol lookup
Select an option...
KRTX Karuna Therapeutics Inc
EFBI Eagle Financial Bancorp Inc
CNSP CNS Pharmaceuticals Inc
DIDIY DiDi Global Inc
QLGN Qualigen Therapeutics Inc
JOFF JOFF Fintech Acquisition Corp
IR Ingersoll Rand Inc
TGT Target Corp
CCLP CSI Compressco LP
BIOT Biotech Acquisition Co
Go

Health Care : Biotechnology | Mid Cap Growth

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on creating and delivering transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is for the treatment of psychosis in Alzheimer's disease (AD), which is the prevalent subtype of dementia-related psychosis (DRP). KarXT is a combination of xanomeline and trospium. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms associated with schizophrenia and dementia-related psychosis (DRP). Its muscarinic receptors serve a number of physiological roles, including in cognitive, behavioral, sensory, motor and autonomic processes.

Postmarket

Last Trade: Delayed
$200.01

Change Since Close Change Since Close Postmarket extended hours change is based on the last price at the end of the regular hours period. Premarket extended hours change is based on the day's regular session close.: 0.00 (0.00%)

Bid: --

Ask: --

B/A Size: --

Market Hours

Closing Price: $200.01

Day's Change: -0.78 (-0.39%)

Bid close: --

Ask close: --

B/A Size: --

Day's High: 204.40

Day's Low: 199.21

Volume (Above Average) Volume: 356,348 10-day average volume: 312,745: 356,348

Yesterday's News, December 06, 2022
6:30 am ET	Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer --Succeeds current president, chief executive officer, and chairman, Steve Paul, M.D., who will transition to president of research and development and chief scientific officer --Christopher Coughlin to assume role of chairman of the board (BusinessWire)
December 04, 2022
9:54 pm ET	Moore Kuehn, PLLC Encourages Investors of Karuna Therapeutics, Inc. to Contact Law Firm New York, New York--(Newsfile Corp. - December 4, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Karuna Therapeutics, Inc. (NASDAQ: KRTX) breached their fiduciary...(Newsfile)
November 03, 2022
6:30 am ET	Karuna Therapeutics Reports Third Quarter 2022 Financial Results and Provides General Business Updates --Phase 3 EMERGENT-3 trial completed enrollment in the fourth quarter of 2022, with topline data anticipated in the first quarter of 2023 --On track to submit New Drug Application (NDA) for KarXT in schizophrenia with the U.S. Food & Drug...(BusinessWire)
November 01, 2022
6:30 am ET	Karuna Therapeutics to Present at the Jefferies 2022 London Healthcare Conference Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Troy Ignelzi, chief...(BusinessWire)
October 11, 2022
9:00 am ET	PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics PsychoGenics Inc. ("PsychoGenics" or the "Company"), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that clinical-stage biopharmaceutical company Karuna Therapeutics, Inc., (NASDAQ: KRTX) has extended...(BusinessWire)
October 06, 2022
4:30 pm ET	Karuna Therapeutics to Present Data from the Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia at the 35th European College of Neuropsychopharmacology (ECNP) Congress Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that data from the Phase 3...(BusinessWire)
September 22, 2022
10:31 am ET	Moore Kuehn, PLLC Encourages Investors of Karuna Therapeutics, Inc. to Contact Law Firm EQNX::TICKER_START (NasdaqGM:KRTX), EQNX::TICKER_END Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Karuna Therapeutics, Inc. (NASDAQ: KRTX) breached their fiduciary duties...(Globe Newswire)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Postmarket

Change Since Close

Market Hours